Fig 1: Targeting TRIB3 in P23H RHO retinas. (A) TRIB3 ablation in P23H RHO mice leads to improvements of scotopic a- and b-wave ERG amplitudes at p45. The ERG waveforms are shown on the bottom. (B) Cell-penetrating peptides targeting TRIB3 activate AKT and protect mice with RD from functional loss. Rd10 mouse retinas were injected with CPPs, Pep2-contr, and Pep2-Ae, delivered by IVT injections. Six hours post-injection, retinas were harvested, and the retinal protein extracts were prepared to run a western blot. A quantitation of normalized p-AKT is shown on the upper panel. Images of the membrane probed with anti-p-AKT and anti-AKT antibodies are shown on the bottom panel (n = 3). (C) P23H RHO mice were injected with Pep2-cont and Pep2-Ae in the left and right eyes, respectively, on p15 and p25. Scotopic ERG amplitudes were registered at p60 (n = 5; * p < 0.05). The representative a- and b-wave amplitudes registered with the control and experimental eyes are shown on the bottom. (D) Treatment of p45 P23H RHO retinal explants cultured in a medium supplemented with 100 μM afatinib for 48 h showed marked reduction in TRIB3. Images of the membrane probed with anti-TRIB3 and anti-actin antibodies are shown on the bottom (n = 6).